October 2025
M	T	W	T	F	S	S
	1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

Science

Haemophilia B – An illustrative review of current challenges and opportunities

Wolfgang Miesbach /LinkedIn

Oct 30, 2025, 07:52

Haemophilia B – An illustrative review of current challenges and opportunities

Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, posted on LinkedIn:

”Excellent illustrated review on haemophilia B just published. Haemophilia B represents only 15% -20 % of haemophilia cases but has distinct challenges.

This compehensive review by Cedric HERMANS MD PhD FRCP (Lon, Edin), Jan Astermark, Sonata Saulyte Trakymiene, and Victor Jiménez-Yuste highlights current insights and clinical advances as well as challenges in haemophilia B care.

The visual content makes it perfect for teaching and patient information:
– Basics – F9 gene (33.5kb, 8 exons), FIX protein (55 kDa), X-linked inheritance
– Clinical picture – bleeding patterns across all severities, quality of life impacts
– Treatment timeline – from 1920s ice packs → plasma → rFIX → EHL products → gene therapy → non-factor therapies
– Tricky situations – inhibitors, surgery protocols, mild/moderate disease
– Pharmacokinetics – why FIX behaves differently (extravascular distribution, collagen IV binding)
– Individualization – matching treatment to patient life, not just labs
– Carriers and research gaps – underserved populations and what we still don’t know

Differences between haemophilia B and haemophilia A:
– Pharmacokinetics: FIX circulates both inside and outside blood vessels
Binds to collagen IV in extravascular tissues (FVIII doesn’t)
Lab tests miss extravascular FIX
– Inhibitors: Lower incidence (1.5-10% vs. 30%) but higher complication rates and ITI only works in 20-30%
– Pregnancy: FIX doesn’t rise like FVIII does – higher bleeding risk for HB carriers during delivery

Gene therapy in haemophilia B:
Haemophilia B was the first target for AAV gene therapy – smaller gene, easier packaging. Recent data show sustained benefit over 10 years

Novel therapies coming:
Anti-TFPI agents & fitusiran (AT siRNA): Subcutaneous options that restore thrombin generation without replacing FIX
No bispecific antibody yet for HB (unlike emicizumab for HA) – but research ongoing

Two neglected populations:
– Mild/moderate HB patients:
May have worse quality of life than severe patients – they bleed unpredictably but rarely get prophylaxis and experience joint damage, hospitalizations, treatment uncertainty.
– Female carriers:
Often undiagnosed or excluded from haemophilia care
FIX doesn’t rise during pregnancy (unlike FVIII)
Only 6% of reported HB population

What we still don’t know:
– Long-term effects of extravascular FIX binding
– Whether cross-reactive material (dysfunctional FIX protein) reduces treatment efficacy
– Optimal dosing for non-factor therapies in HB
– Gene therapy safety beyond 10 years
– How to better diagnose and treat female carriers”

Read the full review here.

Title: Haemophilia B: An illustrative review of current challenges and opportunities

Authors: Cedric Hermans, Jan Astermark, Sonata Šaulytė Trakymienė, Víctor Jiménez-Yuste

Haemophilia B

Stay updated with Hemostasis Today.

Bleeding Diosrders Cedric Hermans Frankfurt University Hospital Haemophilia B Health Hematology Hemostasis Hemostasis Today International Society on Thrombosis and Haemostasis ISTH Jan Astermark Medicine rpth RPTH Journal Sonata Šaulytė Trakymienė thrombosis Víctor Jiménez-Yuste Wolfgang Miesbach

From Inspiration to Recognition: ASCO Awards FASCO Title to Gevorg Tamamyan

Sabine Eichinger Highlights Plenary Lecture on Stroke Mechanisms at ECTH2025

Michael Makris on Biomarin's Decision to Divest Roctavian

The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH

Davide Capodanno: This Time It’s About the Timing of Complete Revascularization in ACS